Niche-based screening identifies small-molecule inhibitors of leukemia stem cells

Nature Chemical Biology

Volumn 9, Issue 12, 2013, Pages 840-848

  Hartwell, Kimberly A ^a,b,c,k   Miller, Peter G ^b,c   Mukherjee, Siddhartha ^d,j   Kahn, Alissa R ^e   Stewart, Alison L ^a   Logan, David J ^a   Negri, Joseph M ^a   Duvet, Mildred ^a,d   Järås, Marcus ^b   Puram, Rishi ^b,c   Dancik, Vlado ^a   Al Shahrour, Fatima ^a,b   Kindler, Thomas ^b   Tothova, Zuzana ^b,c   Chattopadhyay, Shrikanta ^a,f   Hasaka, Thomas ^a   Narayan, Rajiv ^a   Dai, Mingji ^a,g   Huang, Christina ^a   Shterental, Sebastian ^b   Chu, Lisa P ^b   Haydu, J Erika ^b   Shieh, Jae Hung ^e   Steensma, David P ^c   Munoz, Benito ^a   Bittker, Joshua A ^a   Shamji, Alykhan F ^a   Clemons, Paul A ^a   Tolliday, Nicola J ^a   Carpenter, Anne E ^a   Gilliland, D Gary ^a,b,c,h,k   Stern, Andrew M ^a,l   Moore, Malcolm A S ^e   Scadden, David T ^a,d,f   Schreiber, Stuart L ^a,g,h   Ebert, Benjamin L ^a,b,c   Golub, Todd R ^a,c,h,i   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Harvard University   (United States)

^g HARVARD UNIVERSITY   (United States)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j Penn Medicine ^*  (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTILEUKEMIC AGENT; BRD 0638; BRD 1319; BRD 1686; BRD 1856; BRD 6491; BRD 6708; BRD 7116; BRD 8404; BRD 9608; CELASTROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; METHIAZOLE; MEVINOLIN; PARBENDAZOLE; PIPERLONGUMINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER PROGNOSIS; CELL FUNCTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL NICHE; STROMA CELL; STRUCTURE ACTIVITY RELATION; TARGET CELL DESTRUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA; LOVASTATIN; NEOPLASTIC STEM CELLS;

EID: 84888014941     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1367     Document Type: Article

References (54)

1. Konopleva, M., Tabe, Y., Zeng, Z. & Andreeff, M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat. 12, 103-113 (2009).
2. McMillin, D.W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483-489 (2010).
3. Somervaille, T.C. & Cleary, M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257-268 (2006).
4. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
5. Guzman, M.L. et al. Nuclear factor-?B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301-2307 (2001).
6. Costello, R.T. et al. Human acute myeloid leukemia CD34+/CD38? progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 60, 4403-4411 (2000).
7. Despeaux, M. et al. Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia 25, 1789-1793 (2011).
8. Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006).
9. Plosker, G.L. & Faulds, D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45, 788-856 (1993).
10. Stentoft, J. The toxicity of cytarabine. Drug Saf. 5, 7-27 (1990).
11. Terpstra, W. et al. Long-term leukemia-initiating capacity of a CD34? subpopulation of acute myeloid leukemia. Blood 87, 2187-2194 (1996).
12. Breems, D.A., Blokland, E.A., Neben, S. & Ploemacher, R.E. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 8, 1095-1104 (1994).
13. Ploemacher, R.E., van der Sluijs, J.P., van Beurden, C.A., Baert, M.R. & Chan, P.L. Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. Blood 78, 2527-2533 (1991).
14. Corral, J. et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85, 853-861 (1996).
15. Carpenter, A.E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
16. Jones, T.R. et al. Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc. Natl. Acad. Sci. USA 106, 1826-1831 (2009).
17. Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000).
18. Hassane, D.C. et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 111, 5654-5662 (2008).
19. Guzman, M.L. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163-4169 (2005).
20. Guzman, M.L. et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427-4435 (2007).
21. Escuin, D. et al. The hematopoietic-specific ?1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle 8, 3914-3924 (2009).
22. Memon, R.A. et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-?) and PPAR-? messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-?-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141, 4021-4031 (2000).
23. Gimble, J.M. et al. Peroxisome proliferator-activated receptor-? activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. 50, 1087-1094 (1996).
24. Wolins, N.E. et al. OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. J. Lipid Res. 47, 450-460 (2006).
25. Naveiras, O. et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460, 259-263 (2009).
26. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
27. Mootha, V.K. et al. PGC-1?-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
28. Park, D.J., Vuong, P.T., de Vos, S., Douer, D. & Koeffler, H.P. Comparative analysis of genes regulated by PML/RAR? and PLZF/RAR? in response to retinoic acid using oligonucleotide arrays. Blood 102, 3727-3736 (2003).
29. Huntly, B.J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587-596 (2004).
30. Moore, M.A., Dorn, D.C., Schuringa, J.J., Chung, K.Y. & Morrone, G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp. Hematol. 35, 105-116 (2007).
31. Gazzerro, P. et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102-146 (2012).
32. Meacham, C.E., Ho, E.E., Dubrovsky, E., Gertler, F.B. & Hemann, M.T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat. Genet. 41, 1133-1137 (2009).
33. Luo, B. et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. USA 105, 20380-20385 (2008).
34. Konstantinopoulos, P.A. & Papavassiliou, A.G. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol. Sci. 28, 6-13 (2007).
35. Bellosta, S., Paoletti, R. & Corsini, A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109, III50-III57 (2004).
36. Langdon, W.Y. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity. Crit. Rev. Oncog. 17, 199-209 (2012).
37. Weiss, R.B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19, 670-686 (1992).
38. Gupta, P.B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659 (2009).
39. Yeh, J.R. et al. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat. Chem. Biol. 5, 236-243 (2009).
40. Sachlos, E. et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149, 1284-1297 (2012).
41. Dimitroulakos, J. et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93, 1308-1318 (1999).
42. Li, H.Y., Appelbaum, F.R., Willman, C.L., Zager, R.A. & Banker, D.E. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101, 3628-3634 (2003).
43. Osmak, M. Statins and cancer: current and future prospects. Cancer Lett. 324, 1-12 (2012).
44. Kornblau, S.M. et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 109, 2999-3006 (2007).
45. Williams, A.B. et al. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 120, 3069-3079 (2012).
46. Nielsen, S.F., Nordestgaard, B.G. & Bojesen, S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792-1802 (2012).
47. Whyte, D.B. et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464 (1997).
48. Rowell, C.A., Kowalczyk, J.J., Lewis, M.D. & Garcia, A.M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272, 14093-14097 (1997).
49. Berndt, N., Hamilton, A.D. & Sebti, S.M. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775-791 (2011).
50. Lobell, R.B. et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758-8768 (2001).
51. Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006).
52. Moore, M.A., Dorn, D.C., Schuringa, J.J., Chung, K.Y. & Morrone, G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp. Hematol. 35, 105-116 (2007).
53. van Os, R.P., de Haan, G. & Dethmers-Ausema, B. In vitro assays for cobblestone area-forming cells, LTC-IC and CFU-C. Methods Mol. Biol. 430, 143-157 (2008).
54. Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151-1161 (2013).